戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ion therapy (ADT) with or without docetaxel (Taxotere).
2 for Procet 8, in comparison to 2826ng/mL for Taxotere.
3  in prostate cancer cells exposed to DIM and Taxotere.
4 tered mitosis and were selectively killed by Taxotere.
5 ected normal FDC-P1 hematopoietic cells from Taxotere.
6 of Adriamycin prevented cell death caused by Taxotere.
7 le of docetaxel in cancer patients receiving Taxotere.
8 ration of the commercial docetaxel solution, Taxotere.
9 to a C9-ketone which is present in Taxol and Taxotere.
10 mpared with corresponding cells treated with taxotere.
11                                              Taxotere 0.001 microM-induced JNK activation started aft
12 bations were synergistic with subsequent 1-h Taxotere 0.01, 0.1 and 1.0 microM incubations in breast
13                         Activation of JNK by Taxotere 0.01, 0.1 and 1.0 microM was observed at 24 h i
14 ion was predicted to be 2.6 times lower than Taxotere (775 vs. 2017hxng/mL, respectively), resulting
15                      In contrast, docetaxel (Taxotere), a closely related antineoplastic agent, did n
16                                              Taxotere, a potent analog of taxol, did not induce any o
17 nt levels for their sensitivity to Taxol and Taxotere, a synthetic taxoid.
18  may provide a benefit beyond treatment with Taxotere alone in advanced, metastatic breast cancer.
19                                              Taxotere, an analogue that stabilizes microtubules as po
20                           When compared with Taxotere, an equivalent dose of docetaxel administered i
21                  Pharmacokinetic modeling of Taxotere and Procet 8 plasma concentrations, and their a
22             MP470 synergizes with docetaxel (taxotere) and is cytotoxic to GIST cells.
23 rmination of the anticancer agent docetaxel (Taxotere) and its formulation vehicle polysorbate 80 (Tw
24 correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fol
25           Tumors from the Cancer Research UK Taxotere as Adjuvant Chemotherapy phase III trial were t
26 ctivation and PARP cleavage induced by 30 nM Taxotere at 48 h were reversed by curcumin, PD169316 and
27 utic agents paclitaxel (Taxol) or docetaxel (Taxotere) both in vitro and in vivo.
28  microtubule-targeted agents vincristine and taxotere but not with 5-fluorouracil or doxorubicin.
29  increase the mice survivability compared to Taxotere (DTX-TS), the FDA-approved formulation of DTX.
30                                    Taxol and taxotere each induced PGHS-2 expression in human monocyt
31 ant microtubule-disrupting agents, including taxotere, epothilone B, discodermolide, vincristine, 2-m
32 potential aryl isoserine side chains for the Taxotere family of tubulin-binding chemotherapeutics.
33 rug release estimates for the fast releasing Taxotere formulation demonstrated accuracy deviation and
34            Paclitaxel (Taxol) and docetaxel (Taxotere) have been shown to inhibit angiogenesis at low
35 izing agents (MTPAs), notably paclitaxel and taxotere, have come to occupy a central role in the trea
36 serum responded only to LPS, not to taxol or taxotere, implying that they act independently of the LP
37 arked enhanced absorption compared with oral Taxotere in minipigs, resulting in relative bioavailabil
38    Also, Adriamycin prevented the effects of Taxotere in normal human lymphocytes.
39  by DIM enhanced the therapeutic efficacy of Taxotere in prostate cancer in general, which could be u
40                 Treatment with paclitaxel or taxotere increased DR4 and/or DR5 protein levels (up to
41 on of the effects of taxol and its analogue, taxotere, indicates that taxotere is capable of inducing
42                We observed that DIM enhanced Taxotere-induced apoptotic death in both cell lines.
43   These data demonstrate the potentiation of Taxotere-induced cell death by ATRA pretreatment in brea
44 days prior to Taxotere treatment potentiated Taxotere-induced JNK activation 24 and 48 h later, an ef
45 t in the chemosensitization of HRPC cells to Taxotere-induced killing.
46                All three inhibitors reversed Taxotere-induced phosphorylation of Bcl-2.
47                Dual therapy with P1pal-7 and Taxotere inhibits the growth of MDA-MB-231 xenografts by
48                                              Taxotere is a cytotoxin effective in treating breast and
49 l and its analogue, taxotere, indicates that taxotere is capable of inducing bcl2 phosphorylation and
50                                              Taxotere kills cells in mitosis.
51 roved anticancer activity compared with i.v. Taxotere, observed in the metastatic lung cancer model i
52                             The Procet 8 and Taxotere plasma profiles, and associated docetaxel hydro
53 lling 2 weeks after first dose of docetaxel (Taxotere(R)) and trastuzumab (Herceptin(R)) chemotherapy
54 xic optic neuropathy secondary to docetaxel (Taxotere(R)) chemotherapy.
55  releasing commercial docetaxel formulation, Taxotere(R), and a delayed releasing nanomicellar formul
56 (Taxol, Bristol-Myers Squibb) and docetaxel (Taxotere, Rhone-Poulenc Rhorer).
57 vity, safety, and tolerability of docetaxel (Taxotere: Rhone-Poulenc Rorer Pharmaceuticals Inc, Colle
58 e in vitro activity of the taxoid docetaxel (Taxotere; Rhone-Poulenc Rorer, Antony, France) in primar
59                           Because docetaxel (Taxotere, RP 56976; Rhone-Poulenc Rorer, Antony, France)
60  PD90598 potentiated the cytotoxic effect of Taxotere selectively in Raf-1-transformed FDC-P1 leukemi
61                                 In contrast, Taxotere selectively killed MRP1-expressing leukemia cel
62  the synergistic cytotoxicity of P1pal-7 and Taxotere, suggesting that Akt is a critical component of
63    When combined, laulimalide and docetaxel (Taxotere) synergistically inhibited migration and tubule
64 ts such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu.
65 hance the therapeutic activity of docetaxel (Taxotere), the most commonly used drug for the treatment
66             Furthermore, whereas none of the Taxotere-treated mice survived longer than 34 days, 33%
67 ls with ATRA 0.01 microM for 3 days prior to Taxotere treatment potentiated Taxotere-induced JNK acti
68 e effect of DIM alone or in combination with Taxotere using LNCaP and C4-2B prostate cancer cells.
69 observed that paclitaxel (Taxol), docetaxel (Taxotere), vinblastine, vincristine, nocodazole, and col
70 g, Procet 8, and commercial DTX formulation, Taxotere, was conducted in bile duct cannulated rats.
71 mycin-resistant cancer cells with Docetaxel (Taxotere), while protecting parental (Adriamycin-sensiti
72 ceptor antagonist (ABT-627; Atrasentan) with Taxotere will be superior in inducing apoptosis in vitro